Integrating necroptosis into pan-cancer immunotherapy: a new era of personalized treatment.

Journal: Frontiers in immunology

PMID: 39717781

Abstract

INTRODUCTION: Necroptosis has emerged as a promising biomarker for predicting immunotherapy responses across various cancer types. Its role in modulating immune activation and therapeutic outcomes offers potential for precision oncology.

Authors

Yan Gao

Department of Rehabilitation Medicine, The First Affiliated Hospital of Shenzhen University, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China.
Sheng Chen

Department of Thoracic Surgery, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
Lei Li

Department of Thoracic Surgery, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.

Keywords

A549 Cells Animals Biomarkers, Tumor Cell Line, Tumor Cell Proliferation Gene Expression Regulation, Neoplastic HMGB1 Protein Humans Immune Checkpoint Inhibitors Immunotherapy Mice Necroptosis Neoplasms Precision Medicine

External Resources

View on PubMed Access via DOI PubMed (39717781)

Integrating necroptosis into pan-cancer immunotherapy: a new era of personalized treatment.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals